[Current Status of Drug Development for Amyotrophic Lateral Sclerosis].

Q3 Medicine Brain and Nerve Pub Date : 2024-11-01 DOI:10.11477/mf.1416202766
Yohei Iguchi, Masahisa Katsuno
{"title":"[Current Status of Drug Development for Amyotrophic Lateral Sclerosis].","authors":"Yohei Iguchi, Masahisa Katsuno","doi":"10.11477/mf.1416202766","DOIUrl":null,"url":null,"abstract":"<p><p>Amyotrophic lateral sclerosis (ALS) is a progressive and fatal disease of motor neuron. Although riluzole and edaravone have been approved for the treatment of ALS, it remains a lethal disease that causes rapid motor impairment, and there is an urgent need to develop more effective treatments. Advances in understanding the pathomechanisms of ALS, efficient clinical trial design, and research support programs have led to many clinical trials for ALS both domestically and internationally.</p>","PeriodicalId":52507,"journal":{"name":"Brain and Nerve","volume":"76 11","pages":"1241-1249"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brain and Nerve","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11477/mf.1416202766","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Amyotrophic lateral sclerosis (ALS) is a progressive and fatal disease of motor neuron. Although riluzole and edaravone have been approved for the treatment of ALS, it remains a lethal disease that causes rapid motor impairment, and there is an urgent need to develop more effective treatments. Advances in understanding the pathomechanisms of ALS, efficient clinical trial design, and research support programs have led to many clinical trials for ALS both domestically and internationally.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[肌萎缩侧索硬化症药物开发现状]。
肌萎缩性脊髓侧索硬化症(ALS)是一种进行性的致命运动神经元疾病。虽然利鲁唑和依达拉奉已被批准用于治疗渐冻人症,但它仍然是一种导致快速运动障碍的致命疾病,因此迫切需要开发更有效的治疗方法。随着对肌萎缩性脊髓侧索硬化症病理机制的了解、高效的临床试验设计和研究支持计划的进展,国内外开展了许多针对肌萎缩性脊髓侧索硬化症的临床试验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Brain and Nerve
Brain and Nerve Medicine-Neurology (clinical)
自引率
0.00%
发文量
0
期刊最新文献
[Associations between Social Isolation, Loneliness, and Addiction]. [Childhood Maltreatment (Inappropriate Nurturing) from Parent to Child Caused by Isolation and Loneliness]. [Childhood Social Isolation and Social Brain Development]. [Epidemiological Findings on Social Isolation and Loneliness]. [Epidemiological Findings on the Influence of Social Isolation and Loneliness on Dementia Risk].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1